Prolonged (≥10 years) use of ARB/ACEi (angiotensin receptor blockers/angiotensin-converting-enzyme inhibitors) in Western populations significantly reduces breast cancer risk, it is disputed to be caused by suppressing renin-angiotensin II pathway and causing consequent downregulation of TF, VEGF, NF-κB and CREB. Here, TF is linked to breast cancer.